Introduction
Cardiovascular disease (CVD) is the most common cause of death in patients with chronic kidney disease (CKD) (1) . The presence of CKD is an independent risk factor for the development of CVD (2, 3) . In CKD patients, CVD is characterized by atherosclerosis with especially pronounced medial thickening and medial calcification (Mönckeberg's sclerosis) (4) . Recent studies have demonstrated that the anti-aging protein Klotho plays a central and specific role in the etiology of CVD in CKD. Levels of Klotho decrease drastically and progressively in CKD, from the earliest CKD stage onward (5-7). Furthermore, Klotho-deficient mice exhibit the typical Mönckeberg's sclerosis as seen in CKD (8) and uremic toxins are shown to silence Klotho by promoter hypermethylation in experimental conditions (9) .
α-Klotho (in this article denoted Klotho) was initially identified in 1997 as a 130 kDa singlepass transmembrane protein that acts as an ageing suppressor in mice (8) . The Klotho gene is mainly expressed in the distal convoluted and connecting tubule in the kidney and contains two internal repeats, termed KL1 and KL2, both at the exterior of cell membranes. Proteolytic cleavage sites are present between KL1 and KL2, and just above the membrane, suggesting that secreted forms may also exist after ectodomain shedding (10) (11) (12) . In addition to these secreted products, a different transcription product exists as an alternatively spliced variant from the same gene, consisting of the KL1 internal repeat (12, 13) . Secreted forms of Klotho can indeed be detected in serum, urine, and cerebrospinal fluid (6, 11) , but also in media from KL-transfected cells (12) .
Klotho-deficient mice (kl/kl mice) exhibit a phenotype that remarkably resembles human ageing, characterised by a short lifespan, atherosclerosis, extensive medial calcification, pulmonary emphysema, and osteoporosis, among many other ageing-related traits (8) . Moreover, murine Klotho-overexpressing phenotypes are characterized by an extended lifespan (~20-30% longer) (14) . In humans as well, Klotho serum levels are inversely correlated with age (15, 16) .
The best recognized function of Klotho is its function in calcium and phosphate homeostasis, both directly on calcium channels and phosphate transporters (17, 18) , and indirectly as a coreceptor, in conjunction with fibroblast growth factor receptor 1 (FGFR1), for the osteocytederived phosphatonin fibroblast growth factor 23 (FGF23) (19, 20) . FGF23 down-regulates the vitamin D-converting enzyme 25-hydroxyvitamin D3 1-α-hydroxylase (CYP27B1), thereby also affecting levels of active vitamin D (21) (22) (23) . The best described function of FGF23 is induction of phosphaturia, by down-regulating the expression of phosphate transporter NaPi 2a in proximal tubular cells, thereby preventing phosphate re-absorption (24) . FGF23 is a strong and independent predictor of dismal outcome in CKD and after renal transplantation (25) , and is associated with total body calcification burden (26) . The presence of a functional receptor, including local Klotho, for FGF23 in the vessel wall could be a link between the strong 136 epidemiological evidence that connects high levels of FGF23 in CKD, and increased all-cause and cardiovascular death (27, 28) .
It is yet to be elucidated, however, how Klotho is involved in atherogenesis. Given the decrease of Klotho in CKD and the high incidence of Mönckeberg's sclerosis in both CKD and in Klotho-deficient mice, the typical arterial calcification may result from a lack of a vasculoprotective effect of Klotho on VSMCs. Indeed, in experimental CKD models in mice, it has been demonstrated that reduced systemic Klotho increases VSMC calcification and atherosclerosis, which can be rescued by administration of exogenous Klotho (6) or by adenovirus-mediated Klotho gene delivery (29) . It is possible that the same FGF23-activated Klotho/FGFR1 signalling takes place in VSMCs, akin to the renal mechanism, which would require full-length membrane-bound Klotho (30) . Indeed, recent claims have been made in support of the hypothesis of endogenous vascular Klotho production (31) (32) (33) (34) (35) (36) . However, claims of absence of Klotho expression have also been reported (37) (38) (39) . Since many of the described methods have not been validated and data on human vasculature are still inconclusive, we aimed to determine whether full-length Klotho expression could be detected in human kidney donor renal arteries and recipient iliac arteries (prone to Mönckeberg's sclerosis), as well as in human atherosclerotic carotid endarterectomy plaques, and in cultured VSMCs.
Methods

Human tissue samples
To assess Klotho expression in vascular tissue, we used surgical leftover healthy kidney donor renal artery specimens (N=11), CKD graft recipient iliac artery specimens (N=10), carotid endarterectomy specimens from patients (N=4), and autopsy-derived elastic arteries (common carotid arteries (N=3), abdominal aorta (N=3), and common iliac arteries (N=3)). As a positive control and for antibody validation, we used human kidneys (N=6). Kidney tissue was derived from nephrectomized kidneys with Renal Cell Carcinoma (RCC). Renal, artery and endarterectomy tissue samples were collected at the University Medical Center Groningen, whereas healthy kidney donor renal artery and CKD graft recipient iliac artery specimens were collected at the VU University Medical Center (VUmc, Amsterdam) during living donor renal transplantation. At the University Medical Center Goningen, all tissue samples were obtained in accordance with Institutional Review Board guidelines. The study protocol was consistent with the Research Code of the University Medical Center Groningen (https://www.umcg.nl/EN/Research/Researchers/General/ResearchCode/Pages/default.asp x) and Dutch national ethical and professional guidelines ("Code of conduct; Dutch federation of biomedical scientific societies"; http://www.federa.org). At the VUmc, the use of vascular leftover tissue for research purposes was approved by the Institutional Review Board and 137 informed consent was obtained prior to inclusion. Use of human material was conform the Declaration of Helsinki. All tissue samples were snap-frozen in liquid nitrogen until cryosections were cut for immunohistochemistry, protein isolation, or RNA isolation. Additional kidney tissue samples were fixed in 10% formalin and embedded in paraffin until sections were cut for immunohistochemistry.
Cell culture
Primary human aortic smooth muscle cells (HASMCs) (ScienCell, CA, USA) from 3 different donors were cultured from passage 1 to passage 22 in Smooth Muscle Cell Medium (ScienCell), containing Smooth Muscle Cell Growth Supplement (ScienCell), 2% v/v fetal bovine serum (FBS, Lonza) and 1% v/v penicillin/streptomycin solution. Culture flasks, plates, and coverslips were coated with 0.0015% w/v poly-L-lysine solution (molecular weight 70,000-150,000, P4707, Sigma-Aldrich, USA) for 2 hours at 37 o C. HK-2 cells (a kind gift from Theo Borghuis) were cultured in DMEM (Lonza), supplemented with 10% FBS, 1% P/S, and 1% L-glutamine (Lonza). Human embryonic kidney (HEK)293 cells were seeded onto fibronectin-coated cover slips (10 mm Ø) and were transiently transfected with lipofectamin® 2000 (Invitrogen, Breda, The Netherlands, 2 μl/μg DNA) for 2 days with or without 2 µg of the human klotho pEF1 vector (kind gift from Dr. Makoto Kuro-O, University of Texas Southwestern Medical School, USA). Cells were cultured at 5% v/v CO2/37 o C. For stainings, cells were fixed in 2% w/v paraformaldehyde (in PBS) and permeabilized with 0.5% v/v Triton X-100.
Immunohistochemistry (IHC)
To assess Klotho expression histologically, we used human kidney as a positive control. We first assessed Klotho expression with IHC. Cryosections (4 µm thick) were mounted on APEScoated glass slides, dried, and fixed in acetone at RT. Formalin-fixed, paraffin-embedded sections (3 µm thick) were de-paraffinized in xylene, re-hydrated in a graded series of ethanol, and antigen retrieval was performed using pre-heated buffers in a microwave for 15 minutes. 
Competition assay
KM2076 and SC-22220 Klotho stainings were performed as described. In addition, the antibody was pre-incubated with a 40-fold molar excess of recombinant human Klotho (4.33 µg for KM2076, 4.00 µg for SC-22220) for 1 hour before incubation of tissue sections. As a negative binding control for specificity, Klotho peptide (Ab75022, Abcam) (unrelated to the KM2076 and SC-22220 epitopes) was used in a 200-fold molar excess. Serial sections were used in all competition assay stainings.
Immunofluorescence (IF)
Immunofluorescence double stainings were used to assess co-localization with distal tubule marker Epithelial Membrane Antigen (EMA; monoclonal mouse IgG2a antibody, clone E29, Dako), distal tubule marker calbindin (polyclonal rabbit anti-calbindin-D28K 1:300) and VSMC marker α-Smooth Muscle Actin (α-SMA; monoclonal mouse IgG2a, antibody clone 1A4, Dako). Stainings were performed as with IHC, using donkey anti-rat Alexa Fluor 568 (Invitrogen, USA; kindly provided by Sander van Putten, Medical Biology, UMCG) or rabbit anti-rat-biotin (E0468, Dako) with Streptavidin Alexa Fluor 555 (Invitrogen, USA) as conjugates for KM2076. Rabbit anti-mouse-FITC (Dako) was used as a conjugate for E29 (anti-EMA), goat anti-mouse IgG2a Alexa Fluor 555 (Invitrogen) as a conjugate for 1A4 (anti-α-SMA), and goat anti-rabbit Alexa Fluor 555 (Invitrogen) as a conjugate for anti-calbindin-D28K. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI).
The staining patterns of KM2076 and SC-22220 were assessed in young (P3) and old (P22) cultured HASMCs, using rabbit anti-rat-HRP (P0450, Dako) or rabbit anti-goat-biotin (E0466) (after avidin and biotin blocking, Vector Labs, USA) and the Tyramide Signal Amplification (TSA) method (1:50 tetramethylrhodamine tyramide reagent (FP1015, Perkin Elmer, USA) in Amplification Diluent (FP1051, Perkin Elmer, USA) or conjugation with Streptavidin-Alexa Fluor 555 (Life Technologies), respectively. Nuclei were counterstained with DAPI. We visualized positive staining using a high-end fully motorized Zeiss AxioObserver Z1 microscope equipped with TissueFAXS Image Analysis Software (TissueGnostics, Austria).
Histochemistry for calcification
Alizarin Red staining was performed to visualise calcification in vascular tissue. Tissue sections were stained for 5 minutes in 2% w/v Alizarin Red solution (pH = 4.2), followed by 20 dips in 1:1 acetone:xylene and 20 dips in xylene.
Western blotting
To assess Klotho expression at the protein level, we lysed vascular and renal tissue and cell pellets in immunoprecipitation buffer (IPB) and determined the protein concentration of lysates using the Pierce BCA Protein measurement kit (Thermo Scintific, USA). We used human kidney and full-length recombinant human Klotho (R&D Systems, USA) as positive controls. A total of 20 μg of protein lysate or 1 ng recombinant human Klotho in PBS (R&D Systems, MN, USA) was mixed with 5x Laemmli sample buffer (containing β-mercaptoethanol). We cast 8% w/v gels and samples were heated for 5 minutes at 95 o C. After loading and separating the proteins, using a voltage of 110 V for 90 minutes, the proteins were blotted on methanolactivated polyvinylidene difluoride (PVDF) membranes for 90 minutes at 300 mA. Aspecific binding sites were blocked in 5% non-fat dry milk in TBST for 1 hour, followed by incubation with primary antibodies (Klotho: 1:500 (KM2076), and β-actin: 1:2000 (SC-47778, Santa Cruz Biotechnology, CA, USA), as well as calponin (ab46794, Abcam), and α-SMA (1A4, Dako), as functional and structural phenotypical smooth muscle markers) in 5% w/v non-fat dry milk/TBST overnight at 4 o C. Incubation with secondary HRP-conjugated antibodies for 1 hour in 1% w/v non-fat dry milk/TBST at RT was followed by detection of band signals with chemiluminescence, using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific, USA) and the ChemiDoc MP Imaging System (Bio-Rad Laboratories, USA).
qRT-PCR
RNA isolation from tissue and cells was performed using the TRIzol method. RNA concentrations were measured on a Nanodrop (Thermo Scientific, USA). For samples with low yields, a SpeedVac was used to increase the RNA concentration. cDNA was synthesized using Superscript II, random primers, and 100 ng of RNA input. cDNA samples were diluted to a concentration of 2 ng/µl. Taqman mix was prepared with 20x gene expression assay mix (human klotho: Hs00183100_m1 (exon 1-2), Hs00934627_m1 (exon 2-3), Hs00935388_m1 (exon 3-4), and Hs00935389_m1 (exon 4-5)), Applied Biosystems, USA). For mouse tissue, the following primer/probe sets were used: Mm00502002_m1 (klotho, exons 4-5), Mm00656724_m1 (egr-1) (which is up-regulated by FGF23 signalling (19, 30) ), Mm00438930_m1 (fgfr1), and Mm03950126_s1 (ywhaz). qRT-PCR was run by heating samples for 2 minutes at 50 o C, 10 minutes at 95 o C, followed by 40 cycles of 15 seconds at 95 o C and 60 seconds at 60 o C. qRT-PCR was performed on the ABI7900HT (Applied Biosystems, 140 USA) or on the LightCycler (Roche Applied Science, Germany). Undefined threshold values were set at 40. The housekeeping gene TATA-binding protein (TBP) was used for relative quantification in human samples and normal kidney cDNA was used as a positive control. Relative mRNA levels were expressed as 2 -ΔCT .
Kl/kl mouse kidney tissue kl/kl and WT mouse kidneys (40) were procured at the Radboud University Medical Center (Nijmegen, The Netherlands). Cryosections were stained as described (IHC/IF) for antibody validation purposes.
FGF23 treatment in a murine UUO model
This experiment was performed in adherence to the NIH Guide for the Care and Use of Laboratory Animals after local IACUC permission was given. We have injected 160 µg/kg of cleavage-resistant FGF23 or vehicle (PBS) intraperitoneally every 12 hours for 10 days in 8 to 9-weeks-old male C57BL/6JOlaHsd mice (N=10 for the FGF23 group, N=10 for the vehicle group). After 3 days of injections, 20 mice were subjected to left kidney unilateral ureteral obstruction (UUO) to induce hydronephrosis with a concomitant rise in FGF23 levels, followed by 7 additional days of FGF23 injections to constantly maintain high FGF23 levels and induce FGF23 signalling. A sham group (N=6) was included that received a sham operation and no FGF23 injections. All mice were anaesthetized using 1.5% of isoflurane by inhalation and adequacy of anaesthesia was monitored by testing rear foot reflexes. Analgesics (buprenorphine 0.05 mg/kg s.c.) were used immediately and 8 hours post-surgery. After 10 days of injections, all mice were sacrificed under anesthesia (ketamine 75 µg/g + dexmedetomidine 1 µg/g in 200 µl saline i.p.) by exsanguination and kidneys and aortas were excised.
Statistical analysis
Normally distributed data are presented as mean ± SD and non-normally distributed data are presented as median [range] . Normality of distributions was assessed using Q,Q plots. Differences between multiple groups were assessed with the Kruskal-Wallis test, followed by Dunn's post-hoc test. A p value < 0.05 was considered significant. For statistical analysis, SPSS version 18.0.3 (Chicago, USA) was used.
Results
Patient characteristics are presented in Table 1 . As shown in Table 1 , we studied arteries from subjects with both normal renal function (living kidney donors) and end-stage renal disease (renal transplant recipients).
Immunohistochemistry for Klotho in vascular and renal tissue
Recipient artery and carotid endarterectomy specimens were characterized by various degrees of medial calcification, whereas healthy donor arteries were not calcified (Fig. 1) . Assessing the donor renal arteries (N=6), recipient iliac arteries (N=6), and carotid endarterectomy plaques (N=8), staining with rat monoclonal anti-Klotho antibody KM2076 or goat polyclonal anti-Klotho antibody SC-22220 was absent (Fig. 1) . We also assessed Klotho expression in the kidney (as a positive control), using a number of antibodies (KM2076, SC-22220, SC-22218, and AF1819), on both human and murine, frozen and formalin-fixed paraffin-embedded (FFPE) kidney tissue. KM2076 exhibited a clean staining pattern in both human (A) and murine (B) renal tubules, which was absent in vascular smooth muscle cells in intrarenal arteries (Fig. 2) . SC-22220 and SC-22218 exhibited a similar staining pattern, be it with more background staining. AF1819 stainings show that this antibody has a very low affinity for human Klotho, considering the virtually negative staining depicted in Figure 2A . However, AF1819 was shown to have a very high affinity for murine Klotho, again exhibiting a tubular staining pattern without any vascular staining (Fig. 2B) . In serial sections, the tubular staining patterns of KM2076 and SC-22220 overlapped completely (Supplementary Figure 1) . Conjugate control stainings for all anti-Klotho antibodies used were negative (data not shown). 
Immunofluorescence for Klotho in vascular and renal tissue
To characterise the staining pattern of KM2076, we performed double labelling of Klotho and cell-type specific markers, clearly showing co-localization with Epithelial Membrane Antigen (EMA), in distal convoluted and connecting tubules, but not with smooth muscle cell marker α-SMA (Fig. 3, A) .
Immunofluorescence for Klotho in cultured HASMCs
We have previously shown Klotho expression with KM2076 in vitro in a renal cortical epithelial cell subset (41) . In our experiments, we used HK-2 cells as a positive control, using KM2076 and SC-22220, confirming expression using PCR (Supplementary Figure 2) and confirming KM2076 staining specificity with HEK cells transfected with a Klotho construct. To confirm the VSMC-specific observation regarding the lack of Klotho positivity in human tissues with KM2076 and SC-22220, we also stained cultured HASMCs, which were negative both in young (P3) and old (P22) passages, as shown in Figure 3 , B.
Western blotting for Klotho
To confirm our results obtained using antibody KM2076 for immunohistochemistry and immunofluorescence and to validate its specificity, we next performed Western blot experiments on renal and arterial protein lysates as well as on recombinant human Klotho. We were able to detect both recombinant human Klotho and renal Klotho with KM2076 on Western blot at 130 kDa, whereas no expression of Klotho in donor arteries (N=5, D1-5), recipient arteries (N=5, R1-5), or endarterectomy plaques (N=5, P1-5) was detected (Fig. 4) . Also, cultured HASMCs (N=2) did not express Klotho, as assessed using antibody KM2076 (Fig.  4) . All samples did express smooth muscle cell markers calponin and α-SMA. Antibody SC-22220 was also specific for Klotho on Western blot, but its sensitivity was lower as compared to KM2076 (Supplementary Figure 3) . Full Western blots for Klotho are shown in Supplementary Figure 4 .
qRT-PCR
Klotho mRNA was clearly and variably expressed in healthy human renal tissue (Fig. 5, A-D) . This variation might be due to differences in amounts of cortical and medullary areas in the tissue fragments used for RNA analysis. Using highly sensitive primer/probe sets against all 145 four exon junctions, we detected extremely low expression of klotho mRNA in donor arteries (N=6), recipient arteries (N=10), carotid endarterectomy plaques (N=4), or other elastic arteries (N=9) (Fig. 5, A-D) . The number of samples used was dependent on RNA yield and housekeeping gene expression. HASMCs repeatedly yielded undefined klotho CT values (below the detection limit of the assay used) with all three primary cell lines (N=2/cell line). To confirm VSMC presence in the arteries under investigation, we detected abundant α-SMA expression in all samples (Fig. 5, E) . The primer/probe sets showed a comparable pattern across different kidney samples (Fig. 5, F) . These data indicate that klotho mRNA expression in vascular tissue is extremely low, and do not support substantial expression of full-length Klotho by VSMCs.
Antibody validation
In addition to comparing different antibody staining patterns, showing specificity for recombinant human Klotho, and showing positive staining Klotho only in transfected HEK cells and not in non-transfected control cells (Figure 3, C) , we performed a competition assay by pre-incubating antibodies with recombinant human Klotho or an unrelated Klotho peptide (Ab75022) not used as the immunogen for KM2076 or SC-22220. KM2076 staining was blocked by pre-incubation with recombinant human Klotho, but not by pre-incubation with Ab75022 or without pre-incubation (Fig. 6, A) . Similarly, the SC-22220 staining pattern was blocked by recombinant human Klotho, but was otherwise present (Fig. 6, A) . Furthermore, staining of kl/kl and wild-type (WT) kidney tissue showed positive staining in the distal convoluted tubules in WT kidney, but not in kl/kl kidney (Fig. 6, B) . To show that the distal convoluted tubules in kl/kl kidney do not express detectable amounts of Klotho, we have performed double labelling with distal convoluted tubule marker calbindin-D28K, showing colocalization in WT kidney, but single calbindin-D28K-positive tubules in kl/kl kidney (Fig. 6, C) . Taken together, these data indicate that both KM2076 and SC-22220 are specific for fulllength membrane-bound Klotho. 
FGF23 signaling is present in kidney and absent in aorta
In a murine unilateral ureteral obstruction (UUO) model with additional FGF23 injections (N=10), significant up-regulation of Early Growth Response protein (EGR) 1 mRNA was found in the contralateral (non-obstructed) kidney as compared to the vehicle group (N=10), KruskalWallis: p = 0.002 (Fig. 7, A) . This up-regulation was absent in FGF23-treated aortas (Fig. 7, B) , Kruskal-Wallis: p = 0.427. This indicates that FGF23 signalling is present in kidney, but absent in aorta. Fgfr1 mRNA was significantly up-regulated in both UUO groups in kidney (KruskalWallis: p = 0.003), but not in aorta (Kruskal-Wallis: p = 0.205) (Fig. 7, C, D) . Klotho was expressed similarly in all contralateral kidneys (Kruskal-Wallis: p = 0.106) (Fig. 7, E) . Klotho expression was barely detectable in aorta, at levels several thousand-fold lower than in kidneys (Fig. 7, F ) and given the lack of egr-1 response in aorta, not functional as such.
Discussion
Based on elaborate attempts to demonstrate the local production or presence of Klotho in the human arterial wall, we conclude that there is no full-length Klotho expression in all human arterial tissue studied. The absence of the Klotho protein was demonstrated by negative immunohistochemistry and immunofluorescence, Western blotting, and was supported by extremely low klotho mRNA expression by qRT-PCR, using several independent and multivalidated methods. Our findings also render unlikely the possibility that the human vasculature possesses Klotho as a component of the classical receptor for FGF23 (19) . However, it is still possible that Klotho is expressed in segmented fashion in arteries that we have not investigated.
Nonetheless, our results hold implications with regard to the hypothesized the canonical route of FGF23 signal transduction in the vessel wall, through membrane-bound Klotho in conjunction with FGFR1c, in FGF23 vasculotoxicity or vasculoprotection. Moreover, in the absence of functional membrane-bound Klotho, the potential protective effects of Klotho on endothelial cells or on the process of vascular calcification may not be the result of autocrine or paracrine effects of locally cleaved membrane-bound Klotho. (42) . The disproval of the hypothesis of endogenous vascular full-length, membrane-bound Klotho production holds important implications with regard to the manner in which the vasculature can be targeted to ameliorate or prevent the development of atherosclerosis or medial calcification (Mönckeberg's sclerosis) in CKD patients. The possibility that systemic Klotho may convey vascular protection implies dependence on a distant Klotho source, for which the kidney is the most likely candidate, although this is also debated (38, 43) . As CKD progresses, the renal Klotho source is exhausted, possibly exacerbating vascular disease. Methods to up-regulate Klotho expression in the kidney could therefore be promising interventions (44) .
Even though we show that there is no FGF23-induced Klotho/FGFR1 signaling in the aorta, our results cannot completely rule out the possibility that FGF23 still has pathological effects on the vessel wall. It was shown recently that FGF23 effects in the heart and in the parathyroid gland can be mediated by a Klotho-independent pathway, using a different intracellular cascade (45, 46) .
Many authors have previously published data addressing the existence of vascular Klotho expression, yielding very different results. Our data strongly refute the presence of functional membrane-bound Klotho in the vasculature, which is in line with seven studies, in which possible Klotho expression in human and mouse arteries was thoroughly investigated (37) (38) (39) (47) (48) (49) (50) . However, thirteen studies have been published opposing our conclusion, showing data indicative of vascular Klotho expression (8, (31) (32) (33) (34) (35) (36) (51) (52) (53) (54) (55) (56) . With these disparities in mind, to comprehensively address this research question about which so many reports detail different findings, we have invested abundant effort in validating the detection methods for full-length Klotho mRNA and protein.
First of all, it is important to note that published findings on vascular Klotho mRNA are, in fact, not at all wholly discordant. At the mRNA level, both in human and in mouse, we find an extremely low amount of Klotho mRNA. All of the studies referenced above that describe Klotho mRNA expression, do so at similarly low levels or converted to arbitrary units, except for a few studies that show data that are negative even at the mRNA level, although one of these studies employed Northern blotting, as opposed to RT-PCR as performed in other studies (47) (48) (49) (50) . Akin to our data, Lindberg et al. (37) also describe murine Klotho mRNA levels in the vasculature around several thousand-fold lower than in renal tissue. It is likely that there is some Klotho expression at the mRNA level in the vasculature, although the expression level is around the detection limit of most assays.
At the protein level, however, the available data are less easily reconciled. In four studies, Klotho expression in vivo and in vitro could not be detected in vascular smooth muscle (37, 38, 49, 50) . To that end, they used KM2076, KM2119, and an unspecified R&D antibody. Both KM2076 and KM2119 have been shown numerous times to be specific for renal 130 kDa Klotho, which is corroborated by our data. On the other hand, eight studies contain data on vascular Klotho at the protein level (32) (33) (34) (35) (53) (54) (55) (56) . To that end, they used Ab75023, an unspecified Abcam antibody, AF1819, Immutopics and Genprice anti-Klotho antibodies, another unspecified anti-Klotho antibody, and ABIN502138, in addition to KM2076 and SC-22220, which were also used in our study. A number of observations is to be made with regard to these data. First of all, if specified, immunoreactivity between alleged vascular Klotho and anti-Klotho antibodies has always yielded a band of around 110-116 kDa (Ab75023, an unspecified Abcam antibody, and an unspecified antibody) (33, 34, 55) , which is unlikely to be the same protein as the 130 kDa Klotho protein found in the kidney. Furthermore, three studies, using AF1819 on murine aorta and rat IgG2a KM2076 on rat aorta, show immunoreactivity with proteins of unspecified weight (32, 35, 53) . It is interesting to note that AF1819 apparently exhibits immunoreactivity with renal Klotho (as seen in our data and in supplemental data from Fang et al. (32, 53) ), however, this renal staining appears to be mutually exclusive with the vascular staining pattern that they show, rendering it unlikely that the vascular and tubular staining patterns pertain to the same protein. Differences in methods may account for our inability to detect a vascular staining pattern with AF1819. In one study, the authors describe Klotho mRNA expression in VSMCs and in aorta and show immunoreactivity in rat aorta, but fail to identify Klotho protein in VSMCs (35) . This may be due to specific culture conditions or a de-differentiation effect of cell culture, but it is also possible that VSMCs are negative for Klotho protein. Lastly, the positive staining patterns described by various authors are vastly different, ranging from a very distinct medial staining pattern (32, 53 ) to a more vague medial staining pattern (33, 35, 56) to exclusive staining in locations of calcification (34, 54) , without any normal medial staining. Vascular immunoreactivity with anti-Klotho antibodies as reported by others may concern a protein related to or unrelated to Klotho, but it is not membrane-bound Klotho as found in the kidney, nor is it functional as such as an FGF23 co-receptor.
In conclusion, having validated the specificity of our antibodies and having applied several independent methods, our elaborate attempts to demonstrate full-length Klotho gene and protein expression in the human arterial wall have yielded negative results in healthy, atherosclerotic, and uremic arterial tissue, and in HASMCs. Although FGF23 signaling in the arterial wall does not occur through Klotho, our observations do not exclude a protective effect of circulating, soluble Klotho on the arterial wall. 
Supplementary methods
Staining on serial sections for Klotho
Serially cut cryosections were stained as described in the Methods section with the following modifications. The tertiary antibody used was an alkaline-phosphatase-conjugated goat antirabbit polyclonal (Dako, D0487), followed by a quaternary antibody (alkaline phosphataseconjugated anti-alkaline phosphatase, Dako, D0651) 1:100 in 1% AB serum/1% BSA/PBS for 30 minutes, followed by the chromogen reaction for 30 minutes in a solution of 20 mg Naphtol AS-Mx (Sigma), 400 µl 10% MgSO4, 100 mg Fast Blue BB (Sigma), and 24 mg levamisole (Sigma) in 100 ml 0.1 M Tris/HCl (pH 8.2).
RNA interference for Klotho
HK-2 cells were transfected in a 12-wells plate using 2 µl lipofectamine RNAiMAX (Life Technologies) per well and a final concentration of 10 nM siRNA (against Klotho: s17914, s225119, and 15204; scrambled, or GAPDH siRNAs, Life Technologies) in 200 µl Opti-MEM reduced serum medium supplied with 1 ml of 10% FCS/DMEM, for 48 h.
